BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

801 related articles for article (PubMed ID: 15235020)

  • 1. Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation.
    Abkevich V; Zharkikh A; Deffenbaugh AM; Frank D; Chen Y; Shattuck D; Skolnick MH; Gutin A; Tavtigian SV
    J Med Genet; 2004 Jul; 41(7):492-507. PubMed ID: 15235020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral.
    Tavtigian SV; Deffenbaugh AM; Yin L; Judkins T; Scholl T; Samollow PB; de Silva D; Zharkikh A; Thomas A
    J Med Genet; 2006 Apr; 43(4):295-305. PubMed ID: 16014699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An analysis of unclassified missense substitutions in human BRCA1.
    Tavtigian SV; Samollow PB; de Silva D; Thomas A
    Fam Cancer; 2006; 5(1):77-88. PubMed ID: 16528611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Classification of BRCA1 missense variants of unknown clinical significance.
    Phelan CM; Dapic V; Tice B; Favis R; Kwan E; Barany F; Manoukian S; Radice P; van der Luijt RB; van Nesselrooij BP; Chenevix-Trench G; kConFab ; Caldes T; de la Hoya M; Lindquist S; Tavtigian SV; Goldgar D; Borg A; Narod SA; Monteiro AN
    J Med Genet; 2005 Feb; 42(2):138-46. PubMed ID: 15689452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Missense variants of uncertain significance (VUS) altering the phosphorylation patterns of BRCA1 and BRCA2.
    Tram E; Savas S; Ozcelik H
    PLoS One; 2013; 8(5):e62468. PubMed ID: 23704879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis.
    Carvalho MA; Marsillac SM; Karchin R; Manoukian S; Grist S; Swaby RF; Urmenyi TP; Rondinelli E; Silva R; Gayol L; Baumbach L; Sutphen R; Pickard-Brzosowicz JL; Nathanson KL; Sali A; Goldgar D; Couch FJ; Radice P; Monteiro AN
    Cancer Res; 2007 Feb; 67(4):1494-501. PubMed ID: 17308087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical classification of BRCA1 and BRCA2 DNA sequence variants: the value of cytokeratin profiles and evolutionary analysis--a report from the kConFab Investigators.
    Spurdle AB; Lakhani SR; Healey S; Parry S; Da Silva LM; Brinkworth R; Hopper JL; Brown MA; Babikyan D; Chenevix-Trench G; Tavtigian SV; Goldgar DE;
    J Clin Oncol; 2008 Apr; 26(10):1657-63. PubMed ID: 18375895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families.
    Vallon-Christersson J; Cayanan C; Haraldsson K; Loman N; Bergthorsson JT; Brøndum-Nielsen K; Gerdes AM; Møller P; Kristoffersson U; Olsson H; Borg A; Monteiro AN
    Hum Mol Genet; 2001 Feb; 10(4):353-60. PubMed ID: 11157798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A high-throughput functional complementation assay for classification of BRCA1 missense variants.
    Bouwman P; van der Gulden H; van der Heijden I; Drost R; Klijn CN; Prasetyanti P; Pieterse M; Wientjens E; Seibler J; Hogervorst FB; Jonkers J
    Cancer Discov; 2013 Oct; 3(10):1142-55. PubMed ID: 23867111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA1/2 germline missense mutations: a systematic review.
    Corso G; Feroce I; Intra M; Toesca A; Magnoni F; Sargenti M; Naninato P; Caldarella P; Pagani G; Vento A; Veronesi P; Bonanni B; Galimberti V
    Eur J Cancer Prev; 2018 May; 27(3):279-286. PubMed ID: 28277317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolutionary conservation analysis increases the colocalization of predicted exonic splicing enhancers in the BRCA1 gene with missense sequence changes and in-frame deletions, but not polymorphisms.
    Pettigrew C; Wayte N; Lovelock PK; Tavtigian SV; Chenevix-Trench G; Spurdle AB; Brown MA
    Breast Cancer Res; 2005; 7(6):R929-39. PubMed ID: 16280041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Marsupial BRCA1: conserved regions in mammals and the potential effect of missense changes.
    Ramirez CJ; Fleming MA; Potter JD; Ostrander GK; Ostrander EA
    Oncogene; 2004 Mar; 23(9):1780-8. PubMed ID: 15001988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A yeast recombination assay to characterize human BRCA1 missense variants of unknown pathological significance.
    Caligo MA; Bonatti F; Guidugli L; Aretini P; Galli A
    Hum Mutat; 2009 Jan; 30(1):123-33. PubMed ID: 18680205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance.
    Chenevix-Trench G; Healey S; Lakhani S; Waring P; Cummings M; Brinkworth R; Deffenbaugh AM; Burbidge LA; Pruss D; Judkins T; Scholl T; Bekessy A; Marsh A; Lovelock P; Wong M; Tesoriero A; Renard H; Southey M; Hopper JL; Yannoukakos K; Brown M; Easton D; Tavtigian SV; Goldgar D; Spurdle AB;
    Cancer Res; 2006 Feb; 66(4):2019-27. PubMed ID: 16489001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolution of the tumor suppressor BRCA1 locus in primates: implications for cancer predisposition.
    Pavlicek A; Noskov VN; Kouprina N; Barrett JC; Jurka J; Larionov V
    Hum Mol Genet; 2004 Nov; 13(22):2737-51. PubMed ID: 15385441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of BRCA1 missense variants V1804D and M1628T on transcriptional activity.
    Ostrow KL; McGuire V; Whittemore AS; DiCioccio RA
    Cancer Genet Cytogenet; 2004 Sep; 153(2):177-80. PubMed ID: 15350310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substantial evidence for the clinical significance of missense variant BRCA1 c.5309G>T p.(Gly1770Val).
    Tudini E; Moghadasi S; Parsons MT; van der Kolk L; van den Ouweland AMW; Niederacher D; Feliubadaló L; Wappenschmidt B; Spurdle AB; Lazaro C
    Breast Cancer Res Treat; 2018 Nov; 172(2):497-503. PubMed ID: 30105462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Classification of rare missense substitutions, using risk surfaces, with genetic- and molecular-epidemiology applications.
    Tavtigian SV; Byrnes GB; Goldgar DE; Thomas A
    Hum Mutat; 2008 Nov; 29(11):1342-54. PubMed ID: 18951461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic, functional, and histopathological evaluation of two C-terminal BRCA1 missense variants.
    Lovelock PK; Healey S; Au W; Sum EY; Tesoriero A; Wong EM; Hinson S; Brinkworth R; Bekessy A; Diez O; Izatt L; Solomon E; Jenkins M; Renard H; Hopper J; Waring P; Tavtigian SV; Goldgar D; Lindeman GJ; Visvader JE; Couch FJ; Henderson BR; Southey M; Chenevix-Trench G; Spurdle AB; Brown MA;
    J Med Genet; 2006 Jan; 43(1):74-83. PubMed ID: 15923272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of a set of missense, frameshift, and in-frame deletion variants of BRCA1.
    Carvalho M; Pino MA; Karchin R; Beddor J; Godinho-Netto M; Mesquita RD; Rodarte RS; Vaz DC; Monteiro VA; Manoukian S; Colombo M; Ripamonti CB; Rosenquist R; Suthers G; Borg A; Radice P; Grist SA; Monteiro AN; Billack B
    Mutat Res; 2009 Jan; 660(1-2):1-11. PubMed ID: 18992264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.